98 related articles for article (PubMed ID: 6871492)
1. [Interactions between complement system and bacterial walls].
Colomb MG; Bensa JC; Chesne S; Aubert B
Bull Eur Physiopathol Respir; 1983; 19(2):131-6. PubMed ID: 6871492
[TBL] [Abstract][Full Text] [Related]
2. Interaction of fluid phase C1/C1q and macrophage membrane-associated C1q with gram-negative bacteria.
Clas F; Euteneuer B; Stemmer F; Loos M
Behring Inst Mitt; 1989 Jul; (84):236-54. PubMed ID: 2552981
[TBL] [Abstract][Full Text] [Related]
3. [Alternative complement activation pathway. Its mechanism, importance and quantitative determination].
Gancevici GG; Popescu C
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(3):209-21. PubMed ID: 6390651
[No Abstract] [Full Text] [Related]
4. Distinct localization of the complement C5b-9 complex on Gram-positive bacteria.
Berends ET; Dekkers JF; Nijland R; Kuipers A; Soppe JA; van Strijp JA; Rooijakkers SH
Cell Microbiol; 2013 Dec; 15(12):1955-68. PubMed ID: 23869880
[TBL] [Abstract][Full Text] [Related]
5. Activation of human complement by Yersinia enterocolitica: ultrastructural alterations and C3b-deposition.
Acker G; Brade V
Zentralbl Bakteriol A; 1980 Nov; 248(2):210-28. PubMed ID: 7223121
[TBL] [Abstract][Full Text] [Related]
6. The fixation of C3b to pneumococcal cell wall polymers as a result of activation of the alternative complement pathway.
Hummell DS; Berninger RW; Tomasz A; Winkelstein JA
J Immunol; 1981 Oct; 127(4):1287-9. PubMed ID: 7024404
[TBL] [Abstract][Full Text] [Related]
7. [Activation of human complement system by bacterial cell walls, their water-soluble enzymatic extracts and related synthetic compounds].
Kawasaki A
Osaka Daigaku Shigaku Zasshi; 1982 Jun; 27(1):46-61. PubMed ID: 6957579
[No Abstract] [Full Text] [Related]
8. [A mechanism of human complement activation by immunostimulators from the bacterial cell wall].
Kozlov LV; Zinchenko AA; Soliakov LS; Sizoĭ MN; Ishchenko AM
Bioorg Khim; 1983 Aug; 9(8):1047-55. PubMed ID: 6680304
[TBL] [Abstract][Full Text] [Related]
9. Antibody-independent killing of gram-negative bacteria via the classical pathway.
Clas F; Loos M
Behring Inst Mitt; 1984 Nov; (76):59-74. PubMed ID: 6525148
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b.
Pangburn MK; Morrison DC; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1980 Feb; 124(2):977-82. PubMed ID: 7356723
[No Abstract] [Full Text] [Related]
11. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.
Edwards MS; Kasper DL; Jennings HJ; Baker CJ; Nicholson-Weller A
J Immunol; 1982 Mar; 128(3):1278-83. PubMed ID: 7035562
[No Abstract] [Full Text] [Related]
12. Subversion of complement activation at the bacterial surface promotes serum resistance and opsonophagocytosis of Francisella tularensis.
Ben Nasr A; Klimpel GR
J Leukoc Biol; 2008 Jul; 84(1):77-85. PubMed ID: 18430786
[TBL] [Abstract][Full Text] [Related]
13. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall.
Winkelstein JA; Abramovitz AS; Tomasz A
J Immunol; 1980 May; 124(5):2502-6. PubMed ID: 7365262
[No Abstract] [Full Text] [Related]
14. Involvement of complement pathways in patients with bacterial septicemia.
Dumestre-Pérard C; Doerr E; Colomb MG; Loos M
Mol Immunol; 2007 Mar; 44(7):1631-8. PubMed ID: 17049606
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
16. Complement activation directly induced by Helicobacter pylori.
Berstad AE; Høgåsen K; Bukholm G; Moran AP; Brandtzaeg P
Gastroenterology; 2001 Apr; 120(5):1108-16. PubMed ID: 11266375
[TBL] [Abstract][Full Text] [Related]
17. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).
Morrison DC; Kline LF
J Immunol; 1977 Jan; 118(1):362-8. PubMed ID: 318670
[TBL] [Abstract][Full Text] [Related]
18. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
Wagner E; Platt JL; Frank MM
J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the alternative pathway of human complement by structural analogues of sialic acid.
Michalek MT; Mold C; Bremer EG
J Immunol; 1988 Mar; 140(5):1588-94. PubMed ID: 3346543
[TBL] [Abstract][Full Text] [Related]
20. The anti-lipid A monoclonal antibody E5 binds to rough gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes.
Seelen MA; Athanassiou P; Lynn WA; Norsworthy P; Walport MJ; Cohen J; Davies KA
Immunology; 1995 Apr; 84(4):653-61. PubMed ID: 7790040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
